Our Radiation Oncologists are affiliated with the University of Sydney and the Radiotherapy Units prides itself in actively participating in research. As it is a leading site in Australia for the delivery of new technology, it is very important that data on all patients receiving treatment is collected. You will be asked to participate in this research.
Ongoing research into treating prostate cancer with a view to improving treatment outcomes for patients is a key focus for our staff. Please speak to your Radiation Oncologist about suitable trials that may be available and eligibility.
Outcomes of our IMRT programme for Post Prostatectomy Radiotherapy
In June 2007, A/Professor Eade and A/Professor Kneebone became the first in Australia to routinely deliver IMRT for all it’s prostate patients (for both post prostatectomy patients and when the prostate is still present). When delivering new technology we feel it is crucial to carefully evaluate outcomes and toxicity.
We have already published outcomes from the first two years of our IMRT programme. It is the first published data in the world looking at quality of life following IMRT for post prostatectomy radiotherapy. We now also have data on biochemical control which is the first in Australia.
Biochemical Control (no rising PSA) following IMRT for Post Prostatectomy Radiotherapy
We have separated PSA control into those patients receiving ‘adjuvant’ radiotherapy within six months of surgery for high risk features versus those having ‘salvage’ treatment for a rising PSA sometimes up to years following their operation.
Those having ‘adjuvant’ treatment had an 85% chance at five years of being ‘cured’ of their cancer versus a 60% chance if they had salvage treatment. Radiotherapy can never result in 100% cure rates as it cannot eradicate cancer if it has spread outside of the pelvis.
Quality of life following IMRT for Post Prostatectomy Radiotherapy
Between June 2007 and December 2013, 265 patients received adjuvant or salvage post prostatectomy IMRT. Of these, 248 patients had their quality of life assessed at baseline and had at least one assessment by five years using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Clinically important changes were defined as a >10 point change in function score.